Evidence map›Paper›PMID 20689585›Full record

Trial reportPloS one2010

Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.

Tamara D Clark, Denise Njama-Meya, Bridget Nzarubara, Catherine Maiteki-Sebuguzi, Bryan Greenhouse, Sarah G Staedke, Moses R Kamya, Grant Dorsey, Philip J Rosenthal

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00123552 (Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00123552 phase3completednot on this map

Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy

TypeinterventionalSponsorUniversity of California, San FranciscoRan2004 to 2008Enrolled601ConditionsMalariaArmsAmodiaquine+Artesunate, Amodiaquine+Sulfadoxine/Pyrimethamine, Artemether+Lumefantrine
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Changing Antimalarial Drug Sensitivities in Uganda.Antimicrobial agents and chemotherapy · 2017
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Malaria Pathogenesis.Cold Spring Harbor perspectives in medicine · 2018
    Review
  15. Article
  16. The American journal of tropical medicine and hygiene · 2017
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Tamara D ClarkDepartment of Medicine, University of California San Francisco, San Francisco, California, United States of America.
Denise Njama-Meya
Bridget Nzarubara
Catherine Maiteki-Sebuguzi
Bryan Greenhouse
Sarah G Staedke
Moses R Kamya
Grant Dorsey
Philip J Rosenthal
Makerere University · UGUniversity of California, San Francisco · USUniversity of London · GB

Funding

Clinical &Molecular Studies of Drug Resistant MalariaU01AI052142 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2003 to 2008
$4.4M
NIAID NIH HHS AI52142NIAID NIH HHS U01 AI052142
6 · The paper itself

Abstract

backgroundCombination therapies are now recommended to treat uncomplicated malaria. We used a longitudinal design to assess the incidence of malaria and compare the efficacies of 3 combination regimens in Kampala, Uganda. METHODOLOGY/PRINCIPAL

findingsChildren aged 1-10 years were enrolled from randomly selected households in 2004-05 and 2007, and were followed at least monthly through 2008. Insecticide-treated bednets (ITNs) were provided in 2006. Children were randomized upon their first episode, and then treated for all episodes of uncomplicated malaria with amodiaquine/sulfadoxine-pyrimethamine (AQ/SP), artesunate/amodiaquine (AS/AQ), or artemether/lumefantrine (AL). Risks of parasitological failure were determined for each episode of uncomplicated malaria and clinical parameters were followed. A total of 690 children experienced 1464 episodes of malaria. 96% of these episodes were uncomplicated malaria and treated with study drugs; 94% were due to Plasmodium falciparum. The rank order of treatment efficacy was AL > AS/AQ > AQ/SP. Failure rates increased over time for AQ/SP, but not the artemisinin-based regimens. Over the 4-year course of the study the prevalence of asymptomatic parasitemia decreased from 11.8% to 1.4%, the incidence of malaria decreased from 1.55 to 0.32 per person year, and the prevalence of anemia (hemoglobin <10 gm/dL) decreased from 5.9% to 1.0%. No episodes of severe malaria (based on WHO criteria) and no deaths were seen. CONCLUSIONS/SIGNIFICANCE: With ready access to combination therapies and distribution of ITNs, responses were excellent for artemisinin-containing regimens, severe malaria was not seen, and the incidence of malaria and prevalence of parasitemia and anemia decreased steadily over time.

trial registrationisrctn.org ISRCTN37517549.

Indexed as

AmodiaquineAntimalarialsArtemetherArtemisininsArtesunateChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationEthanolaminesFemaleFluorenesHumansIncidenceInfantLumefantrineAmodiaquineAntimalarialsArtemetherArtemisininsArtesunateDrug CombinationsEthanolaminesfanasil, pyrimethamine drug combinationFluorenesLumefantrinePyrimethamineSulfadoxine

Identifiers

PMID20689585
PMCPMC2912768
OpenAlexW2021293206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.